Viemed Healthcare Earnings Call Highlights Growth Amid Shift

Viemed Healthcare US ((VMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Viemed Healthcare struck an upbeat tone on its latest earnings call, highlighting record revenue, strong cash generation, and a growing sleep and maternal health platform. Management acknowledged regulatory headwinds that are temporarily slowing ventilator growth, but stressed a solid balance sheet, robust January trends, and successful appeals as reasons to stay confident in the long-term trajectory.

Record topline growth and EBITDA strength

Viemed reported full-year 2025 revenue of $270.3 million, up about 21% from the prior year, with fourth-quarter sales reaching $76.2 million for 26% growth. Adjusted EBITDA set a new high at $61.4 million for the year, implying a margin near 22.7%, while Q4 adjusted EBITDA came in at $18.2 million, underscoring operating leverage despite regulatory transition.

Free cash flow more than doubles

Cash generation was a major bright spot as net cash from operating activities hit $51.9 million in 2025. Free cash flow more than doubled to $28.1 million, including $10.8 million in the fourth quarter, and with $13.5 million of net cash plus $46 million in available credit and only $11.3 million of long-term debt, Viemed is effectively operating with no net leverage.

Sleep and resupply emerge as growth engines

The company’s PATH therapy program and related sleep services saw rapid expansion, with PATH patient counts reaching 34,528 at year-end, a 62% increase. New sleep patient setups jumped 70% in 2025, resupply patients climbed 49% to 36,561, and sleep’s contribution to revenue rose from 16% to 20%, making this category an increasingly important growth driver.

Broader revenue mix reduces dependency on vents

Viemed continued to diversify away from its core ventilator business, as ventilation’s share of revenue dropped from 56% to 51% while other segments scaled quickly. Equipment and supply sales grew by roughly $19.4 million or 63%, ventilator rentals increased about $12.2 million or 10%, non-vent home medical equipment rentals rose around $9.7 million or 20%, and services revenue added $4.8 million, up roughly 24%, with maternal health contributing about 3% of total sales.

Accretive acquisition fuels maternal health opportunity

The acquisition of Lehan’s Medical Equipment, which closed midyear, integrated smoothly and was immediately accretive to net income. Maternal health revenue reached approximately $9 million in 2025, and management framed the business as a scalable new growth engine that complements Viemed’s respiratory and sleep footprint.

Regulatory execution and operations show resilience

On the regulatory front, Viemed emphasized its documentation and compliance strengths by reporting a 100% success rate in Administrative Law Judge appeals on Medicare Advantage denials tied to the new coverage rules. The company also noted that January 2026 was among the strongest months ever for new ventilator setups, suggesting early signs that the operational adjustments are beginning to pay off.

Capital returns and disciplined allocation

Capital allocation remains shareholder-friendly but measured, with the board authorizing a new share repurchase program for 2026 after the company bought back about 5% of its shares in 2025 at an average price of $6.69. Management plans to balance buybacks with continued investment in growth areas, targeting 2026 revenue between $310 million and $320 million and adjusted EBITDA of $65 million to $69 million.

Ventilator growth moderates under new coverage rules

Despite the positive overall picture, the company did see a slowdown in ventilator patient growth in the fourth quarter as the industry adjusted to an updated national coverage determination. Under the new criteria, some patients who previously qualified may no longer be eligible, creating near-term friction that pressures volumes, even as Viemed works to refine patient selection and documentation.

Seasonality and near-term revenue headwinds

Management cautioned that the first quarter of 2026 is expected to be flat to slightly down sequentially as the NCD transition plays out alongside typical seasonal factors. The team flagged that growth in 2026 will likely be uneven by quarter, with a softer start followed by a reacceleration from the second quarter onward once the new processes are fully embedded.

Higher compliance burden raises operating complexity

The updated coverage rules brought heavier documentation and workflow demands, requiring more compliance staffing, physician education, and internal process tightening. These efforts have added short-term costs and complexity, but management framed them as necessary investments to protect reimbursement and support sustainable growth in its ventilator and related service lines.

Respiratory therapist staffing and service capacity

Viemed also reported a sequential decline in respiratory therapist headcount during 2025, explaining that staffing is tied closely to patient volumes and the mix of locations. If ventilator patient growth remains subdued for longer than expected, service revenue could come under pressure, but management believes volume recovery will allow RT resources to be deployed more efficiently over time.

EBITDA growth to lag revenue on tough comparisons

Investors should expect 2026 adjusted EBITDA growth to trail the pace of revenue expansion, as last year’s numbers benefited from non-recurring items. The company highlighted a $2.2 million gain from a ventilator buyback program in 2025 as one example, which will make year-over-year margin expansion harder to achieve even as overall profitability continues to rise.

Scaling challenges in maternal health rollout

While maternal health is an exciting new vertical, management was candid about the operational lift required to scale it beyond Lehan’s existing footprint. Success will depend on securing payer contracts, understanding state-level reimbursement nuances, building local sales capabilities, and expanding back-office fulfillment, all of which introduce execution risk as the company ramps up quickly.

Guidance points to continued growth despite uneven cadence

For 2026, Viemed guided to net revenue of $310 million to $320 million, implying roughly 17% year-over-year growth, and adjusted EBITDA of $65 million to $69 million, with margins expected to remain stable despite the absence of last year’s one-time gains. Management anticipates a flat to slightly down first quarter, then sequential growth of about 3% to 5% from the second quarter onward, while maintaining disciplined capital spending at roughly 10% to 11.5% of revenue to support technology and compliance investments.

Viemed’s earnings call painted the picture of a company successfully diversifying beyond its core ventilator business and using strong cash flow to support both growth and shareholder returns. While regulatory changes are creating short-term noise in ventilator volumes and margins, management’s confidence, early signs of recovery, and a solid balance sheet suggest the underlying growth story remains intact for long-term investors.